216 related articles for article (PubMed ID: 24036604)
21. MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death.
Jiao P; Zhou YS; Yang JX; Zhao YL; Liu QQ; Yuan C; Wang FZ
Mol Cell Biochem; 2013 Oct; 382(1-2):217-24. PubMed ID: 23797319
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
[TBL] [Abstract][Full Text] [Related]
23. Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma.
Li Z; Yan S; Attayan N; Ramalingam S; Thiele CJ
Clin Cancer Res; 2012 Jul; 18(13):3603-15. PubMed ID: 22550167
[TBL] [Abstract][Full Text] [Related]
24. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.
Xu S; Li S; Guo Z; Luo J; Ellis MJ; Ma CX
Mol Cancer Ther; 2013 Aug; 12(8):1665-75. PubMed ID: 23689832
[TBL] [Abstract][Full Text] [Related]
25. Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway.
Liu JS; Huo CY; Cao HH; Fan CL; Hu JY; Deng LJ; Lu ZB; Yang HY; Yu LZ; Mo ZX; Yu ZL
Phytomedicine; 2019 Aug; 61():152843. PubMed ID: 31039533
[TBL] [Abstract][Full Text] [Related]
26. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.
Chen KF; Chen HL; Tai WT; Feng WC; Hsu CH; Chen PJ; Cheng AL
J Pharmacol Exp Ther; 2011 Apr; 337(1):155-61. PubMed ID: 21205925
[TBL] [Abstract][Full Text] [Related]
27. MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines.
Almhanna K; Cubitt CL; Zhang S; Kazim S; Husain K; Sullivan D; Sebti S; Malafa M
Cancer Biol Ther; 2013 Oct; 14(10):932-6. PubMed ID: 23917345
[TBL] [Abstract][Full Text] [Related]
28. Combination of aloin and metformin enhances the antitumor effect by inhibiting the growth and invasion and inducing apoptosis and autophagy in hepatocellular carcinoma through PI3K/AKT/mTOR pathway.
Sun R; Zhai R; Ma C; Miao W
Cancer Med; 2020 Feb; 9(3):1141-1151. PubMed ID: 31830378
[TBL] [Abstract][Full Text] [Related]
29. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
30. Suppression of AKT anti-apoptotic signaling by a novel drug candidate results in growth arrest and apoptosis of hepatocellular carcinoma cells.
Cuconati A; Mills C; Goddard C; Zhang X; Yu W; Guo H; Xu X; Block TM
PLoS One; 2013; 8(1):e54595. PubMed ID: 23355882
[TBL] [Abstract][Full Text] [Related]
31. Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.
Neri LM; Cani A; Martelli AM; Simioni C; Junghanss C; Tabellini G; Ricci F; Tazzari PL; Pagliaro P; McCubrey JA; Capitani S
Leukemia; 2014 Apr; 28(4):739-48. PubMed ID: 23892718
[TBL] [Abstract][Full Text] [Related]
32. MK2206 inhibits hepatocellular carcinoma cellular proliferation via induction of apoptosis and cell cycle arrest.
Wilson JM; Kunnimalaiyaan S; Gamblin TC; Kunnimalaiyaan M
J Surg Res; 2014 Oct; 191(2):280-5. PubMed ID: 24996256
[TBL] [Abstract][Full Text] [Related]
33. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-760 Inhibits Doxorubicin Resistance in Hepatocellular Carcinoma through Regulating Notch1/Hes1-PTEN/Akt Signaling Pathway.
Tian T; Fu X; Lu J; Ruan Z; Nan K; Yao Y; Yang Y
J Biochem Mol Toxicol; 2018 Aug; 32(8):e22167. PubMed ID: 29968951
[TBL] [Abstract][Full Text] [Related]
35. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma.
Liu YL; Yang PM; Shun CT; Wu MS; Weng JR; Chen CC
Autophagy; 2010 Nov; 6(8):1057-65. PubMed ID: 20962572
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of LncRNA NR027113 inhibits cell proliferation and metastasis via PTEN/PI3K/AKT signaling pathway in hepatocellular carcinoma.
Chen Z; Zhou ZY; He CC; Zhang JL; Wang J; Xiao ZY
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(21):7222-7232. PubMed ID: 30468465
[TBL] [Abstract][Full Text] [Related]
37. Long Noncoding RNA lncARSR Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Modulating PTEN-PI3K/Akt Pathway.
Li Y; Ye Y; Feng B; Qi Y
J Cell Biochem; 2017 Dec; 118(12):4498-4507. PubMed ID: 28464252
[TBL] [Abstract][Full Text] [Related]
38. Matrine derivative WM130 inhibits hepatocellular carcinoma by suppressing EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways.
Qian L; Liu Y; Xu Y; Ji W; Wu Q; Liu Y; Gao Q; Su C
Cancer Lett; 2015 Nov; 368(1):126-134. PubMed ID: 26259512
[TBL] [Abstract][Full Text] [Related]
39. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
40. Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma.
Kunter I; Erdal E; Nart D; Yilmaz F; Karademir S; Sagol O; Atabey N
Oncol Rep; 2014 Feb; 31(2):573-80. PubMed ID: 24337632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]